Therapeutic Asset Ratings

502 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Osimertinib Head And Neck Neoplasm	AstraZeneca	P1	CC (41)
Rosuvastatin Advanced Solid Malignancies	AstraZeneca	P1	CC (41)
1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) Endometrial Cancer	AstraZeneca	P1/2	CC (41)
azd3470 Hodgkins Lymphoma	AstraZeneca	P1/2	CC (41)
azd3470 Lymphoma	AstraZeneca	P1/2	CC (41)
azd4360 Gastric Cancer	AstraZeneca	P1/2	CC (41)
azd4360 Pancreatic Ductal Adenocarcinoma	AstraZeneca	P1/2	CC (41)
azd5305 Cervical Cancer	AstraZeneca	P1/2	CC (41)
azd5305 Endometrial Carcinoma	AstraZeneca	P1/2	CC (41)
azd5305 Gastric Cancer	AstraZeneca	P1/2	CC (41)
azd5851 Hepatocellular Carcinoma	AstraZeneca	P1/2	CC (41)
azd5863 Gastric Cancer	AstraZeneca	P1/2	CC (41)
azd5863 Pancreatic Ductal Adenocarcinoma	AstraZeneca	P1/2	CC (41)
azd6750 Head And Neck Squamous Cell Carcinoma	AstraZeneca	P1/2	CC (41)
azd6750 Melanoma	AstraZeneca	P1/2	CC (41)
azd6750 Renal Cell Carcinoma	AstraZeneca	P1/2	CC (41)
azd6750 Triple-Negative Breast Carcinoma	AstraZeneca	P1/2	CC (41)
azd7789 Gastric Cancer	AstraZeneca	P1/2	CC (41)
azd8853 Non-Small Cell Lung Carcinoma	AstraZeneca	P1/2	CC (41)
AZD9793 Hepatocellular Carcinoma	AstraZeneca	P1/2	CC (41)
Camizestrant Cervical Cancer	AstraZeneca	P1/2	CC (41)
Camizestrant Endometrial Carcinoma	AstraZeneca	P1/2	CC (41)
Camizestrant Gastric Cancer	AstraZeneca	P1/2	CC (41)
Datopotamab Deruxtecan Cervical Cancer	AstraZeneca	P1/2	CC (41)
Palacaparib Endometrial Carcinoma	AstraZeneca	P1/2	CC (41)

Showing 351 to 375 of 502 assets

PreviousPage 15 of 21Next